The Relative Strength (RS) Rating for Stryker jumped into a new percentile Friday, with an increase from 77 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history shows that the top-performing stocks often have an RS Rating of at least 80 as they launch their biggest climbs.
Stryker is working on a consolidation with a 406.19 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
Earnings-per-share growth dropped last quarter from 16% to 14%, but revenue rose from 11% to 12%.
The company earns the No. 10 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
